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TNFα Contributes to Diabetes Impaired Angiogenesis in Fracture Healing
Abstract
Diabetes increases the likelihood of fracture, interferes with fracture healing and impairs angiogenesis. The
latter may be significant due to the critical nature of angiogenesis in fracture healing. Although it is known that
diabetes interferes with angiogenesis the mechanisms remain poorly defined. We examined fracture healing in
normoglycemic and streptozotocin-induced diabetic mice and quantified the degree of angiogenesis with
antibodies to three different vascular markers, CD34, CD31 and Factor VIII. The role of diabetes-enhanced
inflammation was investigated by treatment of the TNFα-specific inhibitor, pegsunercept starting 10 days after
induction of fractures. Diabetes decreased both angiogenesis and VEGFA expression by chondrocytes. The
reduced angiogenesis and VEGFA expression in diabetic fractures was rescued by specific inhibition of TNF
in vivo. In addition, the TNF inhibitor rescued the negative effect of diabetes on endothelial cell proliferation
and endothelial cell apoptosis. The effect of TNFα in vitro was enhanced by high glucose and an advanced
glycation endproduct to impair microvascular endothelial cell proliferation and tube formation and to
stimulate apoptosis. The effect of TNF, high glucose and an AGE was mediated by the transcription factor
FOXO1, which increased expression of p21 and caspase-3. These studies indicate that inflammation plays a
major role in diabetes-impaired angiogenesis in endochondral bone formation through its effect on
microvascular endothelial cells and FOXO1.
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Abstract
Diabetes increases the likelihood of fracture, interferes with fracture healing and impairs 
angiogenesis. The latter may be significant due to the critical nature of angiogenesis in fracture 
healing. Although it is known that diabetes interferes with angiogenesis the mechanisms remain 
poorly defined. We examined fracture healing in normoglycemic and streptozotocin-induced 
diabetic mice and quantified the degree of angiogenesis with antibodies to three different vascular 
markers, CD34, CD31 and Factor VIII. The role of diabetes-enhanced inflammation was 
investigated by treatment of the TNFα-specific inhibitor, pegsunercept starting 10 days after 
induction of fractures. Diabetes decreased both angiogenesis and VEGFA expression. The reduced 
angiogenesis and VEGFA expression in diabetic fractures was rescued by specific inhibition of 
TNF in vivo. In addition, the TNF inhibitor rescued the negative effect of diabetes on endothelial 
cell proliferation and endothelial cell apoptosis. The effect of TNFα in vitro was enhanced by 
high glucose and an advanced glycation endproduct to impair microvascular cell proliferation and 
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stimulate apoptosis. The effect of TNF, high glucose and an AGE was mediated by the 
transcription factor FOXO1, which increased expression of p21 and caspase-3. These studies 
indicate that inflammation plays a major role in diabetes-impaired angiogenesis in endochondral 
bone formation through its effect on microvascular endothelial cells and FOXO1.
Keywords
blood vessel; cytokine; endothelial; forkhead; hyperglycemia; inflammation; vascularization; 
VEGF
Introduction
Diabetes impairs bone formation and delays fracture healing, presenting a challenge in the 
management of diabetic fractures. Diabetics also have more complications during fracture 
healing [1–3]. Fracture healing requires angiogenesis and an adequate blood supply [4, 5]. 
Interference with angiogenesis impairs fracture healing [6, 7] while treatment with 
angiogenic factors such as VEGFA and FGF-2 improves bone formation during repair [8, 9]. 
Diabetes leads to reduced angiogenesis that may contribute to the pathologic outcomes in 
diabetic complications [10]. Endothelial progenitor cells are significantly reduced in type 1 
and 2 diabetic patients and in animal models [11]. Injection of CD34+ endothelial 
progenitors in diabetic mice augments vascularization and improves wound healing [12] and 
the application of angiogenic factors promotes vascularization and diabetic fracture healing 
in a rat model [13]. Although it is known that diabetes reduces angiogenesis in fracture 
repair the mechanisms for this decrease have not been established [13].
Diabetes has been shown to increase inflammation in fracture calluses that promotes early 
cartilage resorption and reduced mesenchymal stem cell numbers [14, 15]. The early 
inflammatory response is beneficial by inducing recruitment of mesenchymal stem cells and 
leukocytes, which produce factors to stimulate tissue repair and angiogenesis [16]. However, 
prolonged inflammation leads to deficient bone formation and impaired fracture healing 
[17–19]. In particular, tumor necrosis factor-alpha (TNFα) levels remain elevated in diabetic 
fractures, resulting in early apoptosis of chondrocytes and mesenchymal stem cells [15, 20]. 
Thus, elevated levels of TNFα later in fracture repair may contribute to poor fracture healing 
in diabetics.
In the current study, we demonstrate that diabetes hampers angiogenesis in areas of 
endochondral ossification during fracture healing and reduces VEGFA expression. Specific 
inhibition of TNFα with pegsunercept after the early phase restored blood vessel formation 
in diabetic fractures. Mechanistically, the TNFα-dependent changes were due to reduced 
expression of VEGFA and reduced proliferation and increased apoptosis of endothelial cells. 
The latter were mediated in vitro by the transcription factor FOXO1. Our findings indicate 
that the vascular deficit associated with fracture healing is due in part to diabetes-enhanced 
TNFα and that the control of inflammation during fracture repair may offer a pragmatic 
approach to augment diabetic fracture healing.
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Materials and Methods
Animals
Diabetes was induced in 8-week-old male CD-1 male mice (Charles River Laboratories, 
Wilmington, MA) with a daily intraperitoneal injection of streptozotocin (STZ, 40mg/kg, 
Sigma-Aldrich, St. Louis, MO) for 5 days. Control mice were treated with vehicle alone 
(10mM citrate buffer). Mice were considered hyperglycemic when blood glucose levels 
were greater than 12.48mmol/l. STZ-induced diabetic mice received insulin treatment 
through insertion of slow release insulin implants as described previously [21] or i.p 
injection of pegsunercept, a TNF specific inhibitor as described below. A simple transverse 
closed fracture of the tibia (insulin studies) or femur (TNF inhibitor studies) was performed 
as previously described [21]. The articular surface of the tibia or femur was exposed and a 
27-gauge spinal needle was inserted for fixation. After closure of the incision a fracture was 
created by blunt trauma. Any fractures not consistent with standardized placement criteria 
(mid-diaphyseal) or grossly comminuted were excluded. Animals were subsequently 
euthanized at the indicated time points. Bone was harvested with most of the muscle and soft 
connective tissue was removed. Mice were hyperglycemic for at least 3 weeks prior to 
fracture. In some experiments, animals were treated with TNF-α inhibitor pegsunercept 
(4mg/kg, Amgen, Thousand Oaks, CA) by intraperitoneal injection every 3 days starting at 
10 days post-fracture [15]. At the onset of experiments normoglycemic groups had mean 
glucose values of 6–8mmol/l and diabetic groups had mean values of 25–28mmol/l, which 
was not significantly affected by treatment with pegsunercept. Diabetic mice treated with 
insulin had mean glucose levels of 6mmol/l. Animals were euthanized at 10, 16 and 22 days 
after fracture. All procedures were approved by the Institutional Animal Care and Use 
Committee (IACUC).
Immunofluorescence/Immunohistochemistry
Fracture samples were fixed and decalcified as previously described [14]. Transverse cross-
sections were cut at 5um closest to the fracture callus center. Sections were deparaffinized 
and subjected to antigen retrieval in 10mM citric acid (pH 6.0) by pressure heating. ESM 
table 1 provides the list of antibodies and reagents utilized from this study. Tyramide 
amplification and 3,3'-Diaminobenzidine or Alexa-546 were used to localize the signals. 
Areas of endochondral ossification or mature bone were examined at 100× or 400× original 
magnification and 5–8 images per specimen were captured using a Nikon Eclipse 90i 
microscope. Image analysis was performed using NIS-Elements software (Nikon) under 
blinded conditions. Blood vessels were described as small or moderate vessels depending on 
the number of endothelial cells associated with the vessel. Blood vessels with 2–4 
endothelial cells lining the vessel were categorized as small blood vessels, while vessels 
with 5 or more cells associated with it were considered moderate vessels. VEGFA 
immunopositive hypertrophic chondrocytes were counted in cartilage areas.
Cell culture, transfection, and qPCR
In vitro experiments were carried out with human microvascular endothelial cells (HMVEC) 
from Cell Systems (Kirkland, WA) and maintained in EGM-2 MV growth medium (Lonza, 
Walkersville, MD) with 5% FBS. HMVECs were transfected with 10nM FOXO1 siRNA 
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using GenMute siRNA transfection reagent according to the manufacturer’s instructions. 
Total RNA was isolated using Quick-RNA MicroPrep kit (Zymo Research, Irvine, CA), and 
real-time PCR was performed on a StepOnePlus real-time PCR system (ABI). Results were 
normalized to gene levels of ribosomal protein L32.
In vitro experiments—HMVECs were grown to 70% confluence and then starved in 
EGM-2 MV medium with 0.1% FBS and without growth supplements for 24hours. Cells 
were then cultured in the same media without or with TNFα (2 or 10ng/mL) for 2 days, 
high glucose supplementation (17mM) for 5 days, or advanced glycation endproduct 
(200µg/mL) (AGE; carboxymethyllysine modified albumin) for 3 days prepared as 
previously described [22]. Apoptosis was measured with annexin-V kit and caspase-3 
antibody. Serum-stimulated proliferation with 5% FBS was measured with p21 antibody and 
BrdU assay kit (Cell Signaling, Danvers, MA) according to manufacturer's instructions. 
Quantification of BrdU was determined using a microplate reader (Infinite M200 PRO, 
Tecan, Morrisville, NC) set to read absorbance at 450nm. Images were captured with a 
Nikon Eclipse 90i microscope and mean fluorescence intensity (MFI) measured using NIS 
Elements software. HMVECs were grown to 70% confluence with 5% FBS EGM2-MV and 
then incubated in media supplemented with TNF (2ng/mL), high glucose (17mM) or an 
AGE, CML-albumin (200µg/mL) for 3 days prepared as previously described [22]. Cells 
were then transferred to 96 well plates coated with Matrigel Basement Membrane Matrix 
(LDEV-free, Corning) in triplicate and cultured in EBM media (Lonza). Formation of tubes 
by human microvascular endothelial cells was examined 18hrs later using HMVECs 
cultured in Matrigel as described [23]. The tube number and tube length per well were 
counted using NIS Elements software (Nikon).
Data analysis
All data are expressed as mean ± standard error. Statistical analyses were determined using 
SPSS software (SPSS, Chicago, IL). Statistical significance was defined as p<0.05. One-way 
ANOVA with Tukey post-hoc test was performed to determine statistical significance at a 
single time point, while two-way ANOVA with Tukey post-hoc was used to analyze data 
across time points.
Results
Diabetes decreases angiogenesis in areas of endochondral bone formation
To examine the effect of diabetes on angiogenesis, immunostaining was carried out in mouse 
fracture calluses 10 and 16 days post-fracture, during which robust angiogenesis takes place 
in association with cartilage removal and new bone formation. Antibody to CD34 was used 
to identify single endothelial progenitor cells as well as newly formed blood vessels. 
Approximately 15% of the total cell population in normoglycemic mice was CD34+ at 10 
and 16 days after fracture (Fig. 1C). The number of CD34+ single cells was decreased in 
diabetic mice by 30% (p<0.05) (Fig. 1C). Insulin treatment reversed this reduction, 
indicating that it was not an artifact of streptozotocin treatment, but rather a direct result of 
diabetes (p<0.05) (Fig. 1C). The number of small and moderate vessels increased between 
days 10 and 16 by approximately 50% concurrent with the transition from cartilage to bone 
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(Fig 1 A, B, D and E)(p<0.05). Diabetes reduced the number of small and moderate sized 
CD34+ vessels by 40–50%, which was rescued by insulin (p<0.05) (Fig 1 A, B, D and E). 
Blood vessels were also identified by antibody to Factor VIII. The number of vessels was 
increased by 65%–80% in normoglycemic mice between day 10 and day 16 (p<0.05) (Fig 
1F–G). Diabetes reduced the number of Factor VIII+ small and moderate sized blood vessels 
at 10 and 16 days by 44–50%, which was rescued by insulin (p<0.05) (Fig 1F–G). The 
number of Factor VIII+ vessels on day 22 were also reduced in the diabetic group, a time 
point when primary bone formation has largely been completed (p<0.05) (Fig. 1H–I).
Diabetes induced reduction in angiogenesis is mediated by elevated TNFα
The hypothesis that elevated TNFα in diabetic animals affected angiogenesis was tested 
with a TNFα-specific inhibitor, pegsunercept starting at 10 days post fracture to not interfere 
with early events in repair. Diabetic animals had reduced numbers of blood vessels which 
was largely restored by inhibition of TNF (Supplemental Fig 1). The number of individual 
CD34+ endothelial cells and the number of small and moderate sized blood vessels was 
reduced by 35–50% in diabetic mice (p<0.05), which was largely reversed by treatment of 
diabetic mice with pegsunercept (p<0.05) (Fig. 2A–C). Pegsunercept had little effect on 
angiogenesis in normal mice (Fig. 2A–C). The same pattern was observed when CD31 or 
Factor VIII was used as a marker of endothelial cells (Fig. 2E–G). Pegsunercept treatment 
rescued the reduction in CD31+ single cells and blood vessels (Fig. 2E–G) and Factor VIII+ 
vessels (Fig. 2H–I) caused by diabetes (p<0.05) but had little effect on angiogenesis in 
normoglycemic controls.
TNF Suppresses VEGFA Expression in Vivo and Inhibits Tube Formation in Vitro
Expression of VEGFA is an important early step in angiogenesis and one of the principal 
drivers of angiogenesis in bone. We assessed VEGFA expression in areas of bone formation 
during fracture healing. Hypertrophic chondrocytes were shown to be high expressers of 
VEGFA (Supplemental Fig 2). Diabetes significantly reduced the number of hypertrophic 
chondrocytes that expressed VEGFA by ~50% compared to normoglycemic fractures 
(p<0.05) (Fig 3A). Treatment of diabetic animals with the TNFα inhibitor pegsunercept 
rescued the negative effect of diabetes on VEGFA expression (p<0.05) (Fig 3A).
Tube formation reflects terminal aspects of blood vessel formation and is a critical step in 
angiogenesis. We examined the impact of three factors that are elevated in diabetes, TNFα, 
an advanced glycation endproduct and the effect of high glucose (Fig 3B and C). Moderate 
doses of TNFα (2ng/ml), AGE (200µg/ml) or high glucose (17mM) inhibited tube 
formation measured as either the number of tubes formed or the total tube length. The 
combination of all three was significantly greater than TNF, AGE or high glucose alone.
TNFα reduces proliferation of endothelial cells
Double immunofluorescence was carried out with antibodies to CD34 and Ki67 to examine 
the effect of diabetes on endothelial cell proliferation in vivo. The total number of 
proliferating Ki-67+ cells was reduced 45–50% by diabetes (p<0.05) (Fig. 4A) and the 
number of proliferating single endothelial cells (Ki67+/CD34+) or proliferating endothelial 
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cells associated with blood vessels was reduced by 40% in diabetic mice (p<0.05) (Fig. 4B). 
Insulin reversed the impaired angiogenesis in the diabetic group (p<0.05) (Fig. 4A–D).
Diabetes-reduced proliferation for all cell types was reversed by treatment with either insulin 
or pegsunercept (p<0.05) (Fig. 4A and 5A). Proliferating single Ki67+/CD34+ endothelial 
cells or those associated with blood vessels were decreased by 40 – 54% in the diabetic 
group and reversed by inhibiting TNF (p<0.05) (Fig. 5B–D). Pegsunercept had little effect in 
the total number of proliferating cells (Fig 5A) or in the number of proliferating endothelial 
cells in normoglycemic mice (Fig. 5B & E). Endothelial cell proliferation was reduced by 
diabetes and largely restored by inhibition of TNF when CD31 was used as a marker of 
endothelial cells (Fig. 5E–G) and little effect was seen in vessels of normoglycemic mice.
TNFα, AGE and HG inhibit endothelial cell proliferation that is FOXO1 dependent
In vitro experiments were carried out with primary cultures of microvascular endothelial 
cells to investigate the impact of TNFα and TNFα in combination with high glucose and 
advanced glycation end-products (AGE) based on evidence that each is elevated by diabetes 
[24]. TNFα, AGE and high glucose each reduced microvascular endothelial cell DNA 
synthesis (p<0.05) (Fig. 6A). Low dose TNFα with high glucose and AGE had a similar 
effect as high dose TNFα (Fig. 6B). We determined whether the transcription factor FOXO1 
mediated the effect of TNFα, AGE and high glucose on vascular endothelial cell 
proliferation. Both the effect of low dose TNFα+HG+AGE and high dose TNFα was 
mediated by FOXO1 as shown by substantial reversal with FOXO1 silencing (p<0.05) (Fig. 
6B). The knockdown efficiency of siFOXO1 was approximately 70% (Supplemental Fig 3).
To better understand the effect of FOXO1 in inhibiting DNA synthesis, p21, which inhibits 
cell cycle progression [25] was measured. TNFα increased p21 mRNA 2-fold and p21 
protein 3.3-fold (p<0.05) (Fig. 9A and C). The addition of high glucose and AGE elevated 
the expression of p21 7.6-fold (p<0.05) (Fig. 9C). High dose TNFα and low dose TNFα
+HG+AGE stimulated p21 was largely reversed by FOXO1 knockdown (p<0.05) (Fig. 9C).
TNFα increases apoptosis of endothelial cells in diabetic fractures
Another potential mechanism for reduced angiogenesis is increased endothelial cell 
apoptosis. The overall level of apoptosis reflected by the total number of TUNEL+ cells was 
increased ~2 fold by diabetes (p<0.05) (Fig. 6A) and restored by insulin treatment. The 
number of TUNEL+/CD34+ single cells and TUNEL+/CD34+ cells associated with blood 
vessels was elevated almost 3-fold in diabetic mice (p<0.05), which was substantially 
improved with insulin treatment (p<0.05) (Fig. 6B–D).
Pegsunercept treatment reversed the level of apoptosis for all cell types in diabetic animals 
but had little effect on the normoglycemic group (p<0.05) (Fig. 7A). Diabetes doubled the 
number of TUNEL+/CD34+ positive apoptotic single endothelial cells or TUNEL+/CD34+ 
endothelial cells associated with blood vessels (p<0.05), which was returned to almost 
normal levels with pegsunercept treatment (p<0.05) (Fig. 7B–D). Pegsunercept had little 
effect on apoptosis in normal mice (Fig. 7A–D).
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The effect of TNFα on microvascular endothelial cell apoptosis and proliferation is 
enhanced by high glucose and an advanced glycation end product
In vitro experiments were carried out with primary cultures of microvascular endothelial 
cells to determine the impact of TNFα with high glucose and advanced glycation end-
products (AGE) that are also elevated by diabetes. TNFα, AGE and high glucose each 
reduced HMVEC DNA synthesis (p<0.05) (Fig. 8A). Low dose TNFα with high glucose 
and AGE had a similar effect as high dose TNFα (Fig. 8C). We determined whether the 
transcription factor FOXO1 mediated the effect of TNFα, AGE and high glucose on vascular 
endothelial cell proliferation. Both the effect of low dose TNFα+HG+AGE and high dose 
TNFα was mediated by FOXO1 as shown by substantial reversal with FOXO1 silencing 
(p<0.05) (Fig. 8C). The knockdown efficiency of siFOXO1 was approximately 70% (Fig 8B 
and D). Endothelial cell apoptosis was also increased by TNFα, AGE and high glucose 
(p<0.05) (Fig. 8E) and substantially reversed by FOXO1 siRNA compared to scrambled 
siRNA (p<0.05) (Fig. 8F).
Caspase-3 is one of the primary effector caspases induced by TNFα. TNFα stimulated a 2.2 
fold increase in caspase-3 mRNA and a 3.9-fold increase in activated caspase-3 protein 
(p<0.05) (Fig. 9B–D). The combination of TNFα, high glucose and AGE led to 6.5-fold 
increase in activated caspase-3, which was attenuated by FOXO1 silencing (p<0.05) (Fig. 
9D). Thus, the addition of an AGE and high glucose to TNFα further stimulates the 
expression of genes that regulate cell cycle and apoptosis in a FOXO1 dependent manner.
Discussion
Studies presented here demonstrate that diabetes markedly reduces angiogenesis in fracture 
healing in areas undergoing new bone formation. Angiogenesis was examined using three 
different markers, CD34, CD31 and Factor VIII to assess the full spectrum of endothelial 
cells. The anti-angiogenic effect of diabetes coincided with a decrease in VEGFA 
expression. Both reduced angiogenesis and reduced VEGFA expression were mediated by 
TNFα as demonstrated by rescue with a TNF-specific inhibitor. Moreover, diabetes 
enhanced apoptosis and decreased proliferation of endothelial cells in vivo. TNFα inhibition 
restored proliferation and prevented apoptosis, leading to a recovery in the number of blood 
vessels found in the fracture callus. TNFα reduced the capacity of microvascular endothelial 
cells to respond to growth factors present in serum in vitro and stimulated apoptosis of 
microvascular endothelial cells. The effect of TNFα was enhanced by other factors elevated 
in diabetics, high glucose and AGEs in a FOXO1 dependent manner.
In this study, markers specific to CD34, CD31 and Factor VIII were used to assess 
angiogenesis in fracture healing. CD34 positive cells in the healing callus represent putative 
endothelial progenitor cells [26]. CD34 is also expressed by endothelial cells in capillaries 
and small blood vessels [27]. CD31 is expressed in immature microvascular endothelial cells 
as well as mature endothelial cells in small to large-size vessels [28] and Factor VIII is 
primarily expressed in mature blood vessels [28]. Diabetes significantly reduced the number 
of endothelial cells and blood vessels regardless of which marker was examined in areas of 
endochondral ossification. This is likely to be problematic as angiogenesis is needed for 
fracture healing and is indispensable for new bone formation [29]. Reduced angiogenesis 
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can be explained by lower levels of endothelial cell proliferation and increased apoptosis. It 
may also be due to reduced numbers of circulating CD34+ and CD31+ cells [30]. Insulin 
treatment restored angiogenesis in diabetic animals, indicating that impaired angiogenesis 
was a direct result of diabetes and not an artifact of streptozotocin treatment.
TNFα expression is dysregulated and prolonged in diabetic fracture calluses and in areas of 
endochondral ossification [15, 20]. We previously reported that local levels of TNFα in the 
fracture callus are increased in diabetic mice compared to normoglycemic mice [15, 20]. 
Although TNFα is reported to be a pro-angiogenic cytokine that is necessary for vascular 
infiltration in tumorigenesis [31] and to promote physiologic fracture healing in the early 
phases [32], our findings indicate that in later stages of diabetic fracture healing TNFα 
interferes with angiogenesis. In contrast, TNFα inhibition in normal animals in the same 
timeframe had little effect on angiogenesis.
The proliferative capacity of microvascular endothelial cells is critical for proper 
angiogenesis [33]. Our results suggest that diabetes reduces the expression of VEGFA and 
that reduced VEGFA expression is rescued by inhibiting TNFα. The results are striking 
given a recent report that VEGFA plays a critical role in angiogenesis as well as osteoblast 
differentiation associated with new bone formation [34]. Moreover, TNFα reduced the 
proliferative capacity of endothelial cells to respond to growth factors. The latter is mediated 
through FOXO1 and enhanced by the presence of other factors that are elevated in diabetes, 
namely, high glucose and advanced glycation end products. Previous studies have shown 
that endothelial progenitor cells isolated from type II diabetic patients have decreased 
proliferative capacity in vitro, consistent with our in vivo data [30]. Elevated TNFα can also 
affect endothelial cell numbers through increased apoptosis. Inhibition of TNFα rescued the 
high levels of endothelial cell apoptosis in vivo, and TNFα in vitro induced endothelial cell 
apoptosis.
We showed that the effect of TNFα, high glucose and an AGE on microvascular endothelial 
cells was mediated by FOXO1. All three reduced endothelial proliferation and increased 
apoptosis. FOXO1 was needed for each of these effects and was shown to enhance 
expression of p21, which reduces progression through the cell cycle and increase caspase-3, 
which is a major effector of apoptosis. TNFα and FOXO1 have also been shown to play a 
role in apoptosis of microvascular endothelial cells in diabetic retinopathy [35]. Our in vitro 
results suggest that the effect of TNF, AGEs and high glucose on endothelial cells is direct 
although this does not rule out an indirect effect from the impact the diabetes on 
hypertrophic chondrocytes. This indirect effect may be important since we show here that 
chondrocytes may be an important source of VEGFA. Thus, FOXO1 mediates at least some 
of the negative effects of diabetes on angiogenesis during fracture healing and as a result is 
likely to impair fracture healing under diabetic conditions. FOXO1 may also have a 
significant effect on chondrocytes in diabetic fractures based on our previous reports that it 
mediates increased chondrocyte apoptosis and expression of chemokines by chondrocytes 
[36, 37].
In summary, diabetes has a significant effect on angiogenesis during fracture repair, reducing 
vessel formation and VEGFA expression, which can be directly linked to the impact of 
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diabetes-induced TNFα dysregulation. Furthermore, TNFα along with other factors present 
in diabetes such as high glucose and an AGE impair the ability of microvascular endothelial 
cells and their progenitors to respond to proliferative factors and promote apoptosis of these 
cells. Effects of TNF, high glucose and AGE may be mediated by FOXO1 that regulates 
antiproliferative and pro-angiogenic factors. In contrast, TNFα levels present during normal 
fracture repair are not problematic and did not limit angiogenesis.
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Highlights
• Diabetes decreased both angiogenesis and VEGFA expression.
• The reduced angiogenesis and VEGFA expression in diabetic fractures was 
rescued by specific inhibition of TNF in vivo.
• TNF inhibition rescued the negative effect of diabetes on reduced endothelial 
cell proliferation and increased endothelial cell apoptosis.
• The effect of TNFα in vitro was enhanced by high glucose and an advanced 
glycation endproduct to impair microvascular cell proliferation and enhance 
apoptosis.
• The effect of TNF, high glucose and an AGE was mediated by the 
transcription factor FOXO1, hich increased expression of p21 and caspase-3.
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Figure 1. Diabetes decreases CD34+ and Factor VIII+ blood vessels in areas of endochondral 
bone formation and mature bone during fracture repair
A: Immunofluorescent images following incubation with anti-CD34+ IgG or matched 
control IgG in normoglycemic mice and B: immunofluorescent images of CD34+ expression 
in normoglycemic (N), diabetic (D) and insulintreated diabetic (I) mice from areas of bone 
formation in 16 day fracture specimens (400× or 100× magnification). C–E: CD34 
immunopositive single cells, small vessels or moderate-sized vessels were analyzed as 
described in the Methods at 10 and 16 days after fracture. F–G: Factor VIII positive blood 
vessels were detected by immunohistochemistry in areas of bone formation at 10 and 16 
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days post fracture. H–I: Factor VIII positive blood vessels were quantified in areas of 
mature bone at 22 days after fracture. N=5–6 per group. *p<0.05 between normal vs diabetic 
groups, **p<0.05 between diabetic and insulin-treated groups, # p<0.05 between 
corresponding groups on day 10 and 16.
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Figure 2. Reduced angiogenesis in diabetic fracture healing is mediated by elevated TNFα
Areas of endochondral ossification from fracture calluses were examined by 
immunofluorescence and immunohistochemistry in normoglycemic mice (N), diabetic mice 
(D) or diabetic mice treated 10 days post-fracture with TNFα-specific inhibitor 
pegsunercept (D+PEG). A–C: CD34 immunopositive cells and blood vessels in fracture 
specimens from normoglycemic, diabetic and diabetic+PEG mice in areas of bone 
formation. D–F: CD31 immunopositive cells and blood vessels were counted in areas of 
bone formation in healing fractures. G–H: Factor VIII immunopositive small and moderate-
sized blood vessels were counted in healing fractures. N=5–6 per group. *p<0.05 between 
normal vs diabetic groups, **p<0.05 between 16-day diabetic and pegsunercept-treated 
diabetic groups.
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Figure 3. VEGFA expression and tube formation are inhibited by TNF
A. VEGFA expression by hypertrophic chondrocytes was measured by immunofluorescence. 
B–C. Tube form by microvascular endothelial cells was examined in vitro without or with 
incubation in media supplemented with an AGE (CML-albumin, 200 ug/ml), TNFα (200ng/
ml), high glucose (17mM) or a combination of all three. Data are expressed as total tube 
length per well (B) or number of discrete tubes per well (C). * P<0.05 compared to untreated 
control; ** P<0.05 compared to individual factors.
Lim et al. Page 18
Bone. Author manuscript; available in PMC 2018 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 4. Proliferation of endothelial cells is decreased in diabetes in areas of endochondral bone 
formation
CD34 and Ki67 positive cells or blood vessels were detected by single or double 
immunofluorescence at 10 and 16 days after fracture. Groups included were normoglycemic 
(N), diabetic (D) or diabetic treated with insulin (I). A: The total percent Ki67 
immunopositive single cells. B: Percent CD34 immunopositive single cells that are also 
Ki67 immunopositive. C–D: Percent CD34 immunopositive blood vessels that are also Ki67 
immunopositive. *p<0.05 between normal vs diabetic groups, **p<0.05 between diabetic 
and insulin-treated groups.
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Figure 5. TNFα inhibition reverses the negative effect of diabetes on endothelial cell proliferation
Fracture calluses were examined in areas of endochondral bone formation in sections 
prepared from normoglycemic mice (N), diabetic mice (D) or diabetic mice treated starting 
10 days post fracture with TNF-specific inhibitor pegsunercept (PEG). CD34 and Ki67 
single and double immunopositive cells or blood vessels were identified by 
immunofluorescence. A: Total percent Ki67 immunopositive single cells. B: Percent CD34 
immunopositive single cells that were also Ki67 immunopositive. C–D: Percent CD34 
immunopositive blood vessels that were also Ki67 immunopositive. E: Percent CD31 
immunopositive single cells that were also Ki67 immunopositive. F–G: Percent CD31 
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immunopositive blood vessels that were also Ki67 immunopositive. N=5–6 per group. 
*p<0.05 between normal vs diabetic groups, **p<0.05 between 16-day diabetic and 
pegsunercept-treated diabetic groups.
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Figure 6. High glucose, TNFα and an AGE inhibit endothelial cell proliferation
Human microvascular endothelial cells (HMVECs) were incubated with TNFα. high 
glucose or an AGE, CMLalbumin. A: DNA synthesis in serum stimulated HMVECs 
incubated with TNFα, AGE or high glucose was measured by BrdU assay. B: HMVECs 
were incubated with TNFα, AGE or high glucose alone or combined TNF (2ng/ml)+AGE 
(200ug/ml)+high glucose (17mM) with or without transfection with scrambled siRNA or 
FOXO1 siRNA and then stimulated with serum (10% FBS) as indicated. C: p21 mRNA 
levels were measured by PCR in TNF stimulated HMVEC following transfection with 
scrambled or FOXO1 siRNA. D: HMVEC were incubated with TNFα or TNFα+high 
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glucose+AGE with or without transfection with scrambled or FOXO1 siRNA. Mean 
fluorescence intensity (MFI) of p21 was measured by quantitative immunofluorescence. + 
indicates P<0.05 cells incubated in low-serum, * indicates P<0.05 compared to matched 
control, ** indicates P<0.05 compared to matched scrambled siRNA control.
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Figure 7. Diabetes enhances endothelial cell apoptosis during fracture healing that is reversed by 
insulin treatment
Sections from fracture calluses were examined in normoglycemic (N), diabetic (D) or 
diabetic plus insulin treated (I) mice in areas of bone formation. CD34 positive cells were 
identified by immunofluorescence and apoptosis was quantified by TUNEL assay. A: Total 
percent single cells that were TUNEL positive. B: The percent CD34 immunopositive single 
cells that were also TUNEL positive. C–D: The percent CD34 immunopositive blood 
vessels that were also TUNEL positive. N=5–6 per group. *p<0.05 between normal vs 
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diabetic groups, **p<0.05 between 16-day diabetic and pegsunercept-treated diabetic 
groups.
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Figure 8. TNF Accounts for Diabetes-enhanced endothelial cell apoptosis during fracture healing
Sections from fracture calluses in normoglycemic (N), diabetic (D) or diabetic mice treated 
with TNFα-specific inhibitor pegsunercept (PEG) starting 10 days post fracture. Sections 
were examined in areas of endochondral bone formation in the healing fracture callus. CD34 
positive cells were identified by immunofluorescence and apoptosis was quantified by 
TUNEL assay. A: TUNEL positive single cells were measured. B: The number of TUNEL 
positive single cells in the CD34 positive single cell population. C–D: TUNEL and CD34 
double positive blood vessels. N=5–6 per group. *p<0.05 between normal vs diabetic 
groups, **p<0.05 between 16-day diabetic and pegsunercept-treated diabetic groups.
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Figure 9. TNFα, high glucose and an AGE regulate the expression of p21 and caspase-3 via 
FOXO1
Human microvascular endothelial cells (HMVECs) were transfected with scrambled or 
FOXO1 siRNA and incubated with TNFα, high glucose or an AGE, CML-albumin as 
indicated. A–B: mRNA expression of p21 (A) and caspase3 (B) were evaluated by real-time 
PCR in HMVECs incubated with TNFα, an AGE, CML-albumin or unmodified albumin 
(AGE-ctrl), or high glucose. C–D: HMVEC were incubated with TNF, high glucose or AGE 
as indicated in cells without or with transfection with FOXO1 siRNA or scrambled siRNA. 
Protein levels of p21 and caspase3 were measured by quantitative immunofluorescence and 
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data expressed as mean fluorescence intensity (MFI). *p<0.05 vs. unstimulated cells, 
**p<0.05 vs. scrambled siRNA controls.
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